The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
To me, today’s RNS says the extra Petahash must have been added very close to month end in October to give us only 167 BTC mined.
Should have been much closer to 178 if added it mid-month (based on relative Mining Difficulty, and days in month).
Need to really get a much better move on with adding the rest this month (if not already doing/done so).
Disproportionately Increased income must have been form Zcash strong run in October?
We tend to focus on CE mark being required, but ISO 13485 certification is necessary too.
“How long does it take to achieve ISO 13485 certification if we have no system in place?
Implementation usually takes 4-6 months for companies with fewer than 50 employees. Larger firms with more than 50 employees and/or multiple locations require more written procedures and involve more people, so implementation usually takes 6-12 months. Complex manufacturing processes (example: sterilization) can also prolong the implementation process.
The timeframe for certification is also dependent upon the availability of Notified Body/Registrar auditors to audit and certify your company – in some markets it may take at least between 6-9 months to schedule an on-site audit so it is critical that these organizations be engaged as early as possible to verify their availability.”
https://www.emergobyul.com/services/worldwide/iso-13485-consulting
Good post JohnnieW! The level of volatility is indeed inherent, both up and down.
Regarding the CNS strand:
The BBC podcast Made of Stronger Stuff published an episode on The Appendix this February which contains a discussion about Parkinsons and interviewed Professor John Cryan. It is worth listening to in general, however the conversation about two types of Parkinsons is interesting and starts around 17 minutes. He mentions a brain imaging study suggesting two types of Parkinsons. 1 “Brain First Parkinsons” and 2. “Gut First Parkinsons” in which there is an accumulation of toxic Alpha-synuclein proteins which are able to travel through the Vagus nerve to the brain and cause degeneration. https://www.bbc.co.uk/sounds/play/p097cpwj
This month it was announced that Professor John Cryan was appointed as University College Cork’s Vice President for Research and Innovation. https://apc.ucc.ie/john-cryan-vpri/
In October 2015 it was announced that Alimentary Pharmabotic Centre’s Microbiome Institute of Cork entered into a €4.8 million research collaboration with 4D Pharma to develop live biotherapeutics for Autism Spectrum Disorder and associated Central Nervous System Disorders. The programme led by Professors John Cryan and Ted Dinan, both renowned for research on the brain-gut axis. https://apc.ucc.ie/apc-announces-e4-8m-autism-spectrum-disorder-research-alliance-with-4d-pharma-plc/
Professors John Cryan and Ted Dinan are co-authors of the bestselling book “The Psychobiotic Revolution: Mood, Food, and the New Science of the Gut-Brain Connection”. 4D Pharma Cork Ltd is a campus company in Cork, Ireland.
For those who enjoy scientific details and papers the 2019 study referenced by Professor John Cryan is here https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd191721
I think the issue here (taking some the heat away for a moment) is that many longstanding shareholders do not feel the company needs a lot/as much investment and have been holding for some time for greater returns and are concerned about the dilution. objectively dilution is still dilution.
I dislike people who give valuations or say multiples of share price (when even 2 x is a multiple) without putting dates along the way.
If people want to do this then have the decency to make your case with dates so you are accountable in some way, otherwise those people are simply ramping and misleading people.
Great couple of posts Wigscoff88. I will only add that meeting/s with FDA to seek fastback approval are coming too...!
March 17th is Nasdaq listing vote date
https://sec.report/Document/0001104659-21-027590/
A lot of money in the US for the right companies in BioPharma, especially Micro-Biome:
BiomX Nasdaq symbol $PHGE (Mcap 16om USD) showing a buy of nearly USD 1 million today -
Print: (US time)
Size: 134,800, Time: 1353 Amount: $943,600.00
In pre-market trading LOAC is up over 12% from Friday’s close which has jumped since RNS of this morning.
$LOAC thread on Stocktwits bulletin board in USA has increased Watchers of LOAC from 650 to 950 in the last week.
Active message volume increasing correspondingly.
https://stocktwits.com/symbol/LOAC
Today it will be very interesting to see pattern of rest of day trading in 4D in UK and in LOAC in US now that news is out to a growing audience across the Atlantic too.
(For those new to USA market: Trading market proper opens at 2:30pm and shuts at 9:00pm (UK times). They can trade Pre and post market hours by paying a premium through their brokerages too).
From today’s RNS:
“As 4D pharma’s nominated advisor to its merger with Longevity Acquisition Corporation, we are restricted and can therefore provide factual comment only until shareholder approval for the merger is sought at a general meeting to be held in the coming weeks.”
Note “to be held in the coming weeks” .
No qualifying language there, such as expected, foreseen etc.!
LOAC stirring today, 7.7% up since open
As it almost guaranteed we will be transitioning to a much more transatlantic market view, I am posting the this link to LOAC in a USA online stock forums.
https://stocktwits.com/symbol/LOAC
You can register to post there (I recognise some others from UK forums under new user names) and Add the stock to your Watchlist. They have an easy to use App too.
You need to get to grips with the Stock tags posting. I have posted in $LOAC referencing $MRK this morning which automatically shows in £MRK group and shows how the exposure can and will grow quickly.
Reckon we all need to start getting to grips with US more...
Hope to see some of you there too. All the best.
LOAC filed SEC form 425 this morning:
https://quantisnow.com/insight/345230?s=s
Emphasis of form is MRx0518.
Synopsis document for US market shows how they sketch out background of 4D Oncology activities to provide context to US markets too.
Shows how US PR agency Stern IR are positioning LBPS for the market.
2 x 4D largeish Buys late reported totalling over £312k:
150,000 shares @118.55p for £177,830 @ 13:42 (showing time 13:42)
&
113,600 shares @118.5p for £134,690 (showing time 13:49)
Good evening all.
(Oh, and LOAC up about 5% for now).
When will listing on Nasdaq be done? This question appears on this and other forums from time to time:
Duncan was asked this in the following short video with Proactive Investors US, published on 20th Oct 2020, and said "...we should expect to complete in mid-January".
https://www.youtube.com/watch?v=R8jTzShAzlA&feature=youtu.be
(Most recent January presentation states "US listing in process – completion expected early Q1 2021").
Go to previousJump to the specified articleSubmit
"Early Q1" - so most are thinking by end of January
xcellent summary of new Management presentation, January 2021, by Devonlad on advfn pasted below
“A couple of notes, highlights that oncology is the core area of focus now.
Slide 11 - Demonstrates value of focus on functionality with MicroRx - highlighted, they are putting a lot of weight on the platform.
Slide 12 - MRx0518 increases immune cell populations associated with anti-tumor response - very clear with breast cancer. Again, reflected in slide 12.
Slide 16 - Very interesting, one patient over 15 months on treatment, no growth in the cancer, another patient on 8 months treatment showing a 64% reduction in the cancer size.
Slide 21 - Just read it, that could be beyond ground breaking! That goes onto slide 22 MRx0029 - Significantly reduces a-synuclein induced neuro-inflammation in vitro all showing a reduction in induced inflammation in U373 Cells, again reflected in the lower chart.
Slide 23 - MRx0029: POTENTIAL NEURO-REGENERATIVE CAPABILITY - If you want to get excited, here it is. MRx0029 Induces dopaminergic neuronal phenotype in neuronal progenitor cells•Parkinson's dsease is characterized by the degeneration and death of dopaminergic neurones - potential to reverse PD, that is amazing! Very clear on the two charts as well.
Slide 25 - 4D is preparing to quickly generate clinically-relevant in-patient data in Parkinson’s disease, we could be getting data on this soonish.
Slide 27 - Re-iterates the deal with Merck, they are clearly expecting further developments here and highlight the cash potential from the deal which includes payments of more than $1bn plus royalties. I also think that slide 28 indicates that there is a lot more potential to the deal: Hundreds of candidate strains screened and characterized in depth
Slide 28 - BLAUTIX - Discussions ongoing with KOLs, regulators and potential partners to guide strategic direction - we might be hearing a bit more on Blautix, fingers crossed.
All imho, my take, dyor, nai.”
See new Management presentation, January 2021 at
https://www.4dpharmaplc.com/application/files/3416/0983/5868/4D_pharma_Corporate_Presentation_Jan_2021.pdf